Malignancy is the most common cause of exudative pleural effusions in middle-aged or elderly patients. ' These patients often develop symptoms of cough, pain, and dyspnea requiring relief of the effusion. Pleural drainage and the instillation of a sclerosing agent is the preferred treatment in most cases, and a wide variety of potential sclerosants exist. A more invasive approach is indicated in absence of an underlying diagnosis and when the effusion has recurred after attempted pleurodesis. 2 For many years, thoracoscopic pleural biopsy has been used in the diagnosis of pleural effusions and has a high diagnostic yield.3 It also may be used to facilitate instillation of sclerosants under vision into the pleural cavity. 4 The August 5. of this incision varied if there was evidence of a loculated effusion on preoperative investigations. After draining the effusion by suction and breaking down any loculations, a careful inspection was made of the pleural cavity. Parietal pleurectomy was performed only if the visceral pleura was not heavily involved in the malignant process, allowing full reexpansion of the underlying lung. This was confirmed by reventilation under vision if necessary. The operation was performed as has been previously described for spontaneous pneumothorax5'6 by blunt dissection using curved artery forceps via two more 2-cm incisions. A near total parietal pleurectomy was performed sparing only the diaphragmatic surface and the central mediastinal pleura. Two intercostal drains were placed, one to the apex and one to the base of the pleural cavity; these were placed on high suction to 100 mm Hg.
Postoperative Care
The patients were extubated at the end of the procedure in the operating room and transferred to a high dependency unit for noninvasive blood pressure and pulse oximetry monitoring overnight. Intravenous morphine was administered via a patientcontrolled analgesia system. Patients were discharged when mobile and when their pain could be controlled by oral medication.
Follow-up Data
Accurate follow-up data have been obtained from surgical outpatient follow-up visits and by communication with the respective general practitioners and respiratory physicians.
RESULTS

Patient Characteristics
Pleurectomy was performed in 19 patients (13 men and 6 women), with a median age of 63 years (range, 51 to 84 years). Respiratory function was impaired; the median FEV1 was 51% of predicted (range, 25 to 97%), and the median forced vital capacity was 56% of predicted (range, 34 to 83%). In all patients, pleural fluid had previously been aspirated for cytologic examination; ten patients also had had a closed pleural biopsy using the Abrams needle and seven patients had undergone thoracic computed tomography. Four patients previously had pleural cytologic examination alone. One patient had previously undergone pleural biopsy by VATS but had subsequently developed a persistent effusion. Surgery was performed for palliative pleurodesis in ten patients, in whom the diagnosis was already known, and for both diagnosis and therapy in the other nine patients.
Surgical Results
The median duration of the procedure was 35 min (range, 15 to 60 min). All patients were extubated in the operating room without the need for reventilation. Postoperative blood loss was not excessive with a median 24-h fall in hemoglobin concentration of 1.1 g/dL (range, 0.3 to 2.5 g/dL). Postoperative pain was not excessive with a median postoperative morphine requirement of 1.25 mg/h (range, 0 to 6.2 mg/h) for the first 12 h. Two patients suffered prolonged postoperative air leaks, but the median postoperative hospital stay was 5 days (range, 2 to 20 days). All patients were successfully discharged from hospital, and no patient died within 30 days of surgery.
Postoperative Histologic Studies
The median maximum specimen size was 27 cm2 (range, 7 to 60 cm2), providing a diagnostic sample in each case. Malignant mesothelioma was present in 13 patients; in the remaining 6 patients, metastatic adenocarcinoma was present (bronchial primary, 4; breast primary, 1; an unknown primary, 1).
Follow-up Data
At current median follow-up of 12 months (range, 4 to 17 months), six patients have died after discharge from the hospital at a median of 4 months (range, 2 to 8 months); four died from metastatic adenocarcinoma and two from mesothelioma. Tumor seeding at the cutaneous site of thoracoscopy developed in five patients (all with mesothelioma); two of these have since died. However, symptomatic recurrent pleural effusions after VATS developed in only three patients (one of whom has died).
DISCUSSION
Surgical intervention in patients with malignant pleural effusions is unlikely to affect the course of the underlying disease. Many of these patients either die from the effects of the effusion, rather than the tumor itself, or suffer significant morbidity. Effective pleurodesis in these patients can improve their quality of life in the terminal stages of their disease.
Chemical pleurodesis via tube thoracostomy using tetracycline7 or talc8 has been used in this group of patients. This frequently, however, results in patchy adhesions, loculated fluid, and trapped lung. Surgical exploration, performed via thoracotomy, allows full mobilization of the lung and effective pleurodesis by parietal pleurectomy. Unfortunately, thoracotomy for malignant pleural effusion has a high associated mortality and morbidity.5
Thoracoscopy has been used for many years in the diagnosis of pleural effusions. The advent of VATS now enables procedures such as pleurectomy to be performed without thoracotomy. Furthermore, we have shown that VATS results in significantly less effect on postoperative pulmonary dysfunction than thoracotomy.9 It is logical, therefore, to now perform as complete a parietal pleurectomy as possible rather than just pleural biopsy in patients with known or suspected malignancy.
There have been reservations about the postoperative complications of hemorrhage and respiratory failure after parietal pleurectomy in these patients.
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While we have had successful early results from this technique, we would stress the importance of careful patient selection. Video-assisted pleurectomy should not be attempted if the visceral pleura is heavily diseased and the underlying lung is trapped, when a pleuroperitoneal shunt may be more appropriate. With minor degrees of visceral pleural thickening, however, we have assessed the potential for lung reexpansion with thoracoscopy before proceeding to pleurectomy with satisfactory results in a number of cases. On initial examination, often the lung appears to be trapped but is found to expand after careful division of adhesions and loculi. However, from our initial results, we must question the value of video-assisted pleurectomy in patients with metastatic adenocarcinoma. As reported by Martini et al,5 we also have found that the survival in these patients is limited by the underlying disease rather than pleural involvement. Video-assisted pleurectomy probably is best reserved for patients with effusions secondary to mesothelioma.
Thoracoscopic talc poudrage also has been used in this group of patients, resulting in a similar recurrent effusion rate as in our series.4 In another small series of patients with effusions secondary to metastatic carcinoma, recurrence rates were higher, mostly in patients with pleural fluid pH values less than 7.2.10 Furthermore, talc poudrage is not without potential respiratory complications, such as acute pneumonitis1l and ARDS.12 We believe another benefit of pleurectomy is the reduction in chest pain associated with mesothelioma and retardation of the underlying disease process, which we have observed in a number of patients. A prospective thoracoscopic trial of pleurectomy vs talc poudrage would be worthwhile to assess comparative effectiveness and morbidity.
In conclusion, we believe that there is a role for surgical palliation in selected patients with malignant pleural effusion. However, VATS offers a surgical alternative to thoracotomy with less operative morbidity. We consider the quality of life in these terminally ill patients to be better after video-assisted pleurectomy than the alternative of repeated admissions for thoracocentesis. VATS is a procedure which merits further assessment.
